Ingrid Vandenborre is a partner based in Skadden's Brussels office. She focuses on EU and international merger control and competition law enforcement. Ms. Vandenborre has particular experience in competition law matters in the pharmaceutical sector. Her notable merger control work includes advising Endo on the Boston Scientific deal and Valeant on the Bausch and Lomb deal; also Mylan Inc. in its proposed US$1.85 billion acquisition of Agila Specialties Private Limited from Strides Arcolab Limited; and Stryker Corporation in its US$1.5 billion acquisition of the neurovascular business of Boston Scientific Corporation. She currently is representing generic pharmaceuticals manufacturer in an appeal against the Commission’s first reverse payment patent settlement decision, having represented the company in the administrative proceedings. She previously was involved in the representation of a pharmaceutical company in relation to an Article 102 action initiated by an EU Member State competition authority based on life cycle management issues, and in the successful appeals before the EU General Court, and subsequently the EU Court of Justice leading to the annulment of a Commission decision finding that GlaxoSmithKline’s pricing policy violated Article 101 by restricting parallel imports between EU Member States.